Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul;17(7):945-948.
doi: 10.2215/CJN.05490522.

Prognostication for C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis

Fernando Caravaca-Fontán  1 , Manuel Praga  1   2
Affiliations
Editorial

Prognostication for C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis

Fernando Caravaca-Fontán et al. Clin J Am Soc Nephrol. 2022 Jul.
No abstract available

Keywords: C3 glomerulopathy; histological and clinical predictors; idiopathic membranoproliferative glomerulonephritis.

PubMed Disclaimer

Comment on

References

    1. Smith RJH, Appel GB, Blom AM, Cook HT, D’Agati VD, Fakhouri F, Fremeaux-Bacchi V, Józsi M, Kavanagh D, Lambris JD, Noris M, Pickering MC, Remuzzi G, de Córdoba SR, Sethi S, Van der Vlag J, Zipfel PF, Nester CM: C3 glomerulopathy - Understanding a rare complement-driven renal disease. Nat Rev Nephrol 15: 129–143, 2019 - PMC - PubMed
    1. Fakhouri F, Le Quintrec M, Frémeaux-Bacchi V: Practical management of C3 glomerulopathy and Ig-mediated MPGN: Facts and uncertainties. Kidney Int 98: 1135–1148, 2020 - PubMed
    1. Caravaca-Fontán F, Díaz-Encarnación MM, Lucientes L, Cavero T, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez A, Pérez de José A, Rabasco C, Rodado R, Fernández L, Pérez Gómez V, Ávila AI, Bravo L, Lumbreras J, Allende N, Sanchez de la Nieta MD, Rodríguez E, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, Cano-Megías M, González F, Shabaka A, López-Rubio ME, Fenollosa MÁ, Martín-Penagos L, Da Silva I, Alonso Titos J, Rodríguez de Córdoba S, Goicoechea de Jorge E, Praga M; Spanish Group for the Study of Glomerular Diseases GLOSEN : Mycophenolate mofetil in C3 glomerulopathy and pathogenic drivers of the disease. Clin J Am Soc Nephrol 15: 1287–1298, 2020 - PMC - PubMed
    1. Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, Radhakrishnan J, Marasa M, Rosenstiel PE, Herlitz LC, Markowitz GS, D’Agati VD, Appel GB: C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 93: 977–985, 2018 - PubMed
    1. Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S: C3 glomerulopathy: Ten years’ experience at Mayo Clinic. Mayo Clin Proc 93: 991–1008, 2018 - PMC - PubMed